Introduction
============

The standard treatment of newly diagnosed multiple myeloma (MM) consists of induction therapy followed by single or tandem autologous stem cell transplant (ASCT).[@b1-cmo-2010-117]--[@b4-cmo-2010-117] However, although survival is improved, the majority of these patients still relapse despite achieving good initial responses and very few are cured from MM. Post ASCT interventions have been sought to delay relapses and possibly increase the number of cured patients. Post ASCT maintenance regimens have been studied with usually some benefits. Until recently, interferon-α (IFN-α) with or without steroids was the main maintenance regimen.[@b5-cmo-2010-117],[@b6-cmo-2010-117]

Since the first report by Mandelli et al[@b7-cmo-2010-117] on the usefulness of IFN-α as a maintenance drug for MM patients, multiple studies, including randomized and meta-analysis studies, have demonstrated conflicting results in regards to the effects of IFN-α maintenance, after conventional or high-dose chemotherapy, on progression-free survival (PFS) and/or overall survival (OS).[@b8-cmo-2010-117]--[@b14-cmo-2010-117] These results, the toxicity profile, and the availability of new effective novel agents have resulted in the decline in using IFN-α for maintenance in MM patients. On the other hand, long-term therapy with interferon in other diseases, such as CML and hairy cell leukemia,[@b15-cmo-2010-117],[@b16-cmo-2010-117] has been well tolerated and resulted in long-term disease-free survival. A hint of long-term effect has been noted in data published by the Italian Multiple Myeloma Study Group on 10 year follow up observations of 9 patients still alive in the interferon-maintained group versus 2 in the unmaintained group.[@b17-cmo-2010-117]

Although IFN-α maintenance post autologous transplant has been shown to be beneficial, not all MM patients can start this treatment due to delayed recovery of blood counts and many more will stop therapy due to significant myelosuppression. Our unpublished data on 33 MM patients who underwent ASCT revealed that 5 of these patients were unable to start IFN-α due to slow hematopoietic recovery (historical control), while 7 more had to discontinue IFN-α due to significant drop in blood counts with grade ≥IV toxicity. Thus, a significant proportion of patients are not able to benefit from IFN-α due to low blood counts after ASCT or IFN-α-induced myelosuppression. These results are consistent with findings reported in other published studies.[@b13-cmo-2010-117],[@b18-cmo-2010-117],[@b19-cmo-2010-117]

GM-CSF has been shown to shorten duration of chemotherapy-induced myelosuppression therapy.[@b20-cmo-2010-117]--[@b24-cmo-2010-117] Furthermore, GM-CSF activates macrophages, increases functional capacity of monocytes, mediates proliferation, maturation and migration of dendritic cells, and increases the production of angiostatin by macrophages that inhibit angiogenesis.[@b25-cmo-2010-117]--[@b27-cmo-2010-117] Because of these multiple functions, some studies have suggested possible GM-CSF anti-tumor activity in patients with melanoma and advanced prostate cancer as well as other tumors.[@b28-cmo-2010-117]--[@b31-cmo-2010-117] The use of GM-CSF/IFN-α combination has been reported in patients with CML in chronic phase and melanoma.[@b32-cmo-2010-117]--[@b34-cmo-2010-117] The addition of GM-CSF allowed the escalation of IFN-α dose in half the patients with CML and showed improvement in overall response rate and the complete cytogenetic responses. No toxicity was attributed to the addition of GM-CSF.[@b32-cmo-2010-117]

In this study, our aim was to determine whether the addition of GM-CSF to IFN-α would allow the use of IFN-α maintenance in higher proportion of MM patients and thus possibly improve its direct anti-myeloma effect and prolong survival.

Patients and Methods
====================

Patients
--------

This trial was a prospective phase II study evaluating the myelotoxicity and effectiveness of combined maintenance with GM-CSF and IFN-α in post-transplant MM patients. The study was approved by the institutional review board. Between January 2003 and June 2007, 27 patients were enrolled after signing informed consent. Eligibility for enrollment to the study included \>15 year of age, no more than 120 days from last ASCT, ECOG performance status ≤2.0, transfusion independence, platelet count above 75,000/mm^3^, absolute granulocyte count (AGC) of ≥1500/mm^3^, satisfactory vital organ function, and no serious active infections. Patients with slow count recovery were allowed to start with single agent GM-CSF in order to improve their count recovery and thus meet the above requirements. Patients with progressive disease were excluded from study.

Clinical data were collected on the stage of disease, time from diagnosis to transplant, the number of prior treatments including radiation therapy, β2-microglobulin (β2M) and results of cytogenetics/FISH analysis. Disease status was evaluated before transplant, at the time of study treatment (IFN-α + GM-CSF) and at the completion of study treatment and response was classified according to the International Myeloma Working Group uniform response criteria.[@b35-cmo-2010-117] At the time of treatment, toxicity was evaluated as an effect of combined GM-CSF with IFN-α, and classified according to the NCI Common Toxicity Criteria (CTC version 3).

Treatment plan
--------------

All patients underwent ASCT according to standard practice at our institution as published before.[@b36-cmo-2010-117] Within 120 days of completion of ASCT/induction treatment, all eligible patients were started on IFN-α and GM-CSF simultaneously Monday, Wednesday, and Friday each week. IFN-α was given subcutaneously with an initial dose of 1 × 10^6^ units with weekly increase up to maximal dose of 4 × 10^6^ if tolerated. GM-CSF was given subcutaneously at 125 μg/m^2^ on the same days as the IFN-α. GM-CSF was provided to patients free of charge for maximum of one year by the sponsor (Immunex/Berlex). After one year, patients could continue on IFN-α with/without GM-CSF off study at the discretion of the treating physician. If at any time while on GM-CSF, the WBC exceeded 20,000/mm^3^, then the GM-CSF dose would be decreased by 50%. If at the time of enrollment AGC was \<1500/mm^3^, the patient would start GM-CSF daily until AGC ≥ 1500/mm^3^ before IFN-α was started. IFN-α treatment was stopped if the PLT count dropped \<50,000/mm^3^ and restarted at a lower dose when the PLT count ≥75,000/mm^3^. Study drugs were to be stopped for persistent constitutional symptoms such as fever/flu like symptoms or significant abnormalities in liver function tests beyond the first two weeks of treatment or later if related to higher IFN dose. Restarting IFN treatment at a lower dose was allowed within two weeks and if the symptoms or abnormalities recurred, then the patient was taken off study.

Statistical analysis
--------------------

In this study, myelotoxicity was assessed using the NCI Common Toxicity Criteria (CTC) version 3 and reported using descriptive statistics.

Effectiveness of maintenance was assessed by PFS. In this intent to treat analysis, the PFS and OS were estimated by Kaplan-Meier method. PFS is the time from first ASCT to either confirmed 25% increase/recurrence of paraprotein, doubling the percentage of plasmacytosis in BM, appearance of new lytic lesions or any combination. Patients were censored at the last follow up. OS is the time from first ASCT to death from any reason. All statistical analyses were performed using the GraphPad software Prism 4 (San Diego, CA).

Results
=======

Patient characteristics
-----------------------

Total of 27 patients signed informed consents; however one patient did not start treatment and was not considered for the analysis. The patient characteristics are shown in [Table 1](#t1-cmo-2010-117){ref-type="table"} and reflect a representative group of MM patients.

Among the 26 study participating patients, 19 were white, six African American, and one Asian. At diagnosis, one patient had stage IA, 11 were stage IIA, one stage IIB, 10 IIIA and three were stage IIIB. The cytogenetics and FISH performed at the time of diagnosis showed that 18 patients had normal karyotype, two had complex abnormalities, 3 with deletion of chromosome 13 and 2 of them showed both deletion of chromosome 13 and complex abnormalities, and two more had other cytogenetic abnormalities. Twenty patients had β2M at diagnosis with a median value of 2.3 mg/L, and 6 of them had values greater than 4 mg/L.

The median number of pre-transplant therapies was 1 (range, 1--3), and 8 of them also received prior radiation therapy. Pre-transplant regimens used included VAD (15 patients), thalidomide/dexamethasone (9 patients), hyper CVAD (2 patients), melphalan (1 patient), and lenalidomide (2 patients). At the time of first transplant, four patients were in complete remission (CR), 10 in very good partial remission (VGPR), 11 in partial response (PR), and one had minimal response (MR).

The median follow up from the completion of IFN/GM-CSF study was 33 months (range 5--66) and that from the first ASCT was 45.5 months (range 14--73). Four patients received planned tandem transplants prior to starting IFN treatment. The conditioning regimen for ASCT was busulfan, cyclophosphamide and etoposide in 16 patients as described before,[@b36-cmo-2010-117] while the rest received melphalan 200 mg/m^2^. There were 5 ASCT and 3 non-myeloablative allogeneic transplants done for relapsed disease after completion of the IFN/GM-CSF treatment.

IFN-α/GM-CSF Treatment
======================

[Table 2](#t2-cmo-2010-117){ref-type="table"} summarizes the statistical analysis of the IFN-α/GM-CSF combined treatment in comparison to single agent IFN-α received by a historical control group of patients treated in our institution. In the study group, the median length of treatment with IFN-α was 11.5 months (range, 1--60), while it was only 8 months (range 0.5--54) in the control group. Two patients from the study group had a slow counts recovery after ASCT and were treated with daily GM-CSF for 2 weeks before adding the IFN. Otherwise all enrolled patients were able to start treatment on time between days 90 and 120 after ASCT. Ten patients prematurely discontinued IFN-α after a median time of 2.5 months (range 1--10 months), five of whom experienced persistent flu-like symptoms, one had elevated liver enzymes, one had both flu-like symptoms and elevated liver enzymes, two relapsed and one patient experienced grade 3 thrombocytopenia. Significant leukopenia was not seen in any of the study patients. These patients who stopped study drugs did not receive other treatments until disease progression. The expected length of treatment with GM-CSF and IFN-α was one year long. However, two patients prematurely discontinued GM-CSF due to skin rash and cellulitis. Nine patients continued on with IFN-α alone after completion of one year combined therapy, four of whom were still on IFN-α as of this analysis.

Patients in the historical control group underwent single ASCT between November 1996 and March 2000. However, only 25 of those patients were able to start the IFN-α while 8 were not able to start the treatment. The reasons for not being able to start included delayed counts recovery (4), thrombocytopenia only (1), early relapse (2), and one unknown reason. The median length of IFN therapy was 8 months (range, 0.5--54). Fourteen patients prematurely discontinued the treatment after median of 3 months (range 0.5--8 months). The reasons for discontinuation included relapse (3), pancytopenia (5), leukopenia (2), flu like symptoms (3), and elevated liver enzymes (1). Despite obvious differences between the two groups in terms of the ability to start therapy with IFN and the number of patients who had to stop IFN, the proportion of patients who discontinued IFN therapy in each group was not significantly different using the logrank test (10 patients in the study group vs. 14 patients in the control group, *P* = 0.325). In addition, the median length of IFN-α treatment was not significantly different between the two groups (11.5 months in the study group versus 8 months in the control, *P* = 0.341). On the other hand, the frequency of myelotoxicity in the study group (1 patient with thrombocytopenia) was significantly less than that seen in the control (7 patients) group (two tailed *P* = 0.0173).

Treatment-related toxicity
--------------------------

The treatment related toxicity of GM-CSF/IFN-α combined therapy is given in [Table 3](#t3-cmo-2010-117){ref-type="table"} and was classified according to the NCI CTC (Version 3). Three patients developed persistently elevated liver enzymes that resulted in discontinuation of therapy in 2 of them. Six patients experienced skin rash/cellulitis mostly related to GM-CSF, 4 of whom had only grade I toxicity while 2 had grade IV. Eight patients developed flu-like symptoms, 3 patients with grade II and 5 patients with grade IV. Two patients had grade II and III thrombocytopenia, 2 patients had grade I fatigue, and another 2 had grade II leukocytosis. None of the patients experienced pancytopenia or leukopenia. There was no grade V toxicity resulting in death or hospitalization.

Outcomes and survival analysis
------------------------------

All patients survived more than one year post-transplant and the disease status was evaluated prior to and at completion of 12-month therapy (see [Table 4](#t4-cmo-2010-117){ref-type="table"}). Prior to treatment initiation, 9 patients were determined to be in PR, 5 in CR, and 12 in VGPR. At the completion of 12-month therapy, the number of patients with PR decreased to 3, CR increased to 8, 9 were still in VGPR while 6 patients relapsed. Three of the relapsed patients were those with chromosome 13/13q deletion and two of them died from progressive disease. Overall, eleven patients (42%) have remained in VGPR/CR since ASCT.

At a median follow up of 45.5 months (range, 14--73) from the first ASCT, 20 patients are still alive, 8 of whom are relapse-free for a minimum of 14 months, and 6 have died. [Figure 1](#f1-cmo-2010-117){ref-type="fig"} shows the Kaplan-Meier estimates of OS and PFS. The 2-year OS probability (±SD) was 0.8 ± 0.08 and the PFS was 0.59 ± 0.1. Median OS was not reached for the study treatment group, while the median PFS was 28 mo.

A sub-analysis of the effects of IFN-α and GM-CSF combination in high-risk patients with β2M \> 4 mg/L, chromosome 13/13q deletion and/or complex abnormalities was performed ([Table 5](#t5-cmo-2010-117){ref-type="table"}). The results indicate that the combination maintenance resulted in long-term PFS and OS in 50% of patients with elevated β2M, however the median PFS for this high-risk group was much shorter (13 mo) than that for the whole study group (28 mo).

Discussion
==========

In this study, we report the use of GM-CSF/IFN-α combination therapy as a maintenance treatment for multiple myeloma patients following single or tandem ASCT. Despite the relatively small number of patients enrolled, our results show that the addition of GM-CSF to IFN-α helps ameliorate the myelotoxicity of the latter. IFN related myelotoxicity is especially frequent and an important impediment to its use in patients after ASCT as reported by others and it can be seen in high numbers of patients.[@b13-cmo-2010-117],[@b18-cmo-2010-117],[@b19-cmo-2010-117] Our results show that the addition of GM-CSF may allow the use of IFN maintenance in more patients and it can significantly reduce the prevalence of cytopenias in comparison to our own historical experience.

The use of the combination was associated with 28 month PFS and the OS was not reached at the time of analysis. These results compare positively with published studies reporting the use of IFN-α maintenance after ASCT.[@b14-cmo-2010-117],[@b38-cmo-2010-117],[@b39-cmo-2010-117]

Despite overcoming the problem of IFN-α induced myelosuppression with GM-CSF, significant number of patients still could not tolerate IFN-α due to other constitutional symptoms. Ways to overcome such effects have been explored by using peginterferon with some improvement in quality of life.[@b40-cmo-2010-117] However, it seems that some patients tolerate IFN without any side effects, while others will have symptoms even with the lowest dose possible. The mechanism for causing these side effects is not known, but the individual variability implies different pharmacodynamic responses between patients as described with other interferons[@b41-cmo-2010-117],[@b42-cmo-2010-117] Future pharmacogenomics research in these patients may be key to improving and individualizing the use of IFN-α in the treatment of MM patients.

The main aim of maintenance therapy after ASCT in MM patients is to improve PFS and possibly OS. Achieving such positive effects depends on some known primary prognostic factors. Although our study showed significant improvement in PFS over our historical control (not published), our sub analysis results also show that some high-risk patients, especially with β2M \> 4 mg/L but not with chromosome 13 deletions, may benefit from IFN-α/GM-CSF maintenance. Our study argues for the continued consideration of IFN-α especially in view of the fact that the current alternative, thalidomide, has significant toxicity and uncertainties.[@b43-cmo-2010-117],[@b44-cmo-2010-117] Furthermore, published studies have all reported problems with tolerability and discontinuation of therapy with lenalidomide,[@b45-cmo-2010-117],[@b46-cmo-2010-117] thalidomide[@b43-cmo-2010-117],[@b44-cmo-2010-117],[@b47-cmo-2010-117]--[@b49-cmo-2010-117] or bortezomib[@b50-cmo-2010-117]--[@b53-cmo-2010-117] due to various severe toxicities including myelosupprssion and infection, neuropathy, deep venous thrombosis and pulmonary emboli. Thus, we suggest that IFN-α is not different than any of these new novel drugs and that expanded combination maintenance therapy, including GM-CSF and IFN-α, should be further investigated. Few studies have been published on combining interferon or peginterferon with thalidomide,[@b54-cmo-2010-117]--[@b56-cmo-2010-117] which showed high rate of adverse effects and intolerance to the combination. Another study reported the use of combination of 13 cis-retinoic acid, dexamethasone and IFN-α as maintenance for MM patients post ASCT.[@b57-cmo-2010-117] Although responses were observed, again many patients discontinued therapy due to side effects. The use of bortezomib and lenalidomide in such combinations might be less toxic and warrants investigation. Although preliminary results show promising outcomes with lenalidomide maintenance, some patients do not respond as well or may not tolerate the drug, and therefore it is important to have other options for second line maintenance such as IFN-α ± GM-CSF or in other combinations. Indeed in this study, we have seen few patients who have remained on IFN-α for many years with sustained complete remission. Perhaps, sequential cycling maintenance therapy, as reported before,[@b58-cmo-2010-117] might also be a better way of overcoming additive toxicity and possibly avoiding/delaying the emergence of resistant myeloma clones.

In summary, our data confirm that the combination of GM-CSF with IFN-α is a tolerable and effective maintenance treatment after ASCT with reduced IFN-α induced myelotoxicity and improved PFS in patients with multiple myeloma. Our results support the continued use of IFN-α as a maintenance therapy for MM patients who have responded. Future studies should investigate the addition of newer novel drugs in combination with GM-CSF and interferon.
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###### 

Patient characteristics.

  **Characteristics**                                              **Study group**
  ---------------------------------------------------------------- ----------------------------------------------------------
  Number of patients                                               26
  Age, years                                                       59 (30--71)[\*](#tfn2-cmo-2010-117){ref-type="table-fn"}
  Sex, M/F                                                         14/12
  Race, W/AA/other                                                 19/6/1
  MM stage                                                         
    I A                                                            1
    II A                                                           11
    II B                                                           1
    III A                                                          10
    III B                                                          3
  Disease status prior to ASCT                                     
    CR                                                             4
    VGPR                                                           10
    PR                                                             11
    MR                                                             1
  ASCT                                                             
    CD34+ cell dose/kg                                             5.1 × 10^6^ (2.5--10)
    Tandem ASCT                                                    4
  Chromosome/FISH[\*\*](#tfn3-cmo-2010-117){ref-type="table-fn"}   
    Normal                                                         18
    Complex                                                        1
    Del 13                                                         1
    Complex/del 13                                                 2
    Other                                                          2
  β2M                                                              2.3 (0.6--9.2)
  Time from diagnosis to ASCT, mo                                  6 (3--25)
  Follow up from last ASCT, mo                                     45.5 (14--73)
  Number of prior therapy                                          1 (1--3)
    Patients with ≥2 regimens                                      6
  Prior radiation therapy                                          8
  Number of salvage transplants                                    
    Autologous                                                     5
    Allogeneic                                                     2

**Notes:**

Data reflects median, (range), otherwise number of patients in each category;

Not all patients had chromosomal studies at diagnosis.

**Abbreviations:** AA, African American; W, white; mo, months; M, male; F, female.

###### 

IFN-α treatment statistics in study (IFN/GM-CSF) versus historical control (IFN only) groups.

  **Patient groups**                **Study group**                                         **Control[†](#tfn7-cmo-2010-117){ref-type="table-fn"}**
  --------------------------------- ------------------------------------------------------- ---------------------------------------------------------
  IFN dose, IU (10^6^)              3 (2--4)[\*](#tfn6-cmo-2010-117){ref-type="table-fn"}   3 (1--4)
  Length of IFN therapy, mo         11.5 (1--60)                                            8 (0.5--54)
  Prematurely discontinued IFN      10                                                      14
    Reasons for discontinuation                                                             
      Flu like symptoms             5                                                       3
      Elevated liver enzymes        1                                                       1
      Both of the above             1                                                       0
      Relapse                       2                                                       3
      Thrombocytopenia only         1                                                       0
      Pancytopenia/Leukopenia       0                                                       7[\*\*](#tfn8-cmo-2010-117){ref-type="table-fn"}
  Prematurely discontinued GM-CSF   2                                                       NA
    Reason for discontinuation                                                              
      Skin rash/cellulitis          2                                                       NA
  Using IFN \> 1 year               9                                                       6
  Currently on IFN                  4                                                       NA

**Notes:**

Results reflect median and (range), otherwise number of patients in each category;

33 patients were included in the historical control group, only 25 received IFN-α therapy while 8 of them were not able to start the IFN treatment due to delayed count recovery (4),thrombocytopenia (1), early relapse (2), and unknown reason (1);

Significantly different with two tailed *P* = 0.0173.

###### 

Treatment-related (IFN+GM-CSF) toxicity using CTC version 3.

  **Symptoms[\*](#tfn10-cmo-2010-117){ref-type="table-fn"}**   **0**   **I**   **II**   **III**   **IV**
  ------------------------------------------------------------ ------- ------- -------- --------- --------
  Liver abnormalities                                                          1        1         1
  Skin rash (cellulitis)                                               4                          2
  Flu-like symptoms                                                            3                  5
  Thrombocytopenia                                                             1        1         
  Fatigue                                                              2                          
  Leukocytosis                                                                 2                  

**Note:**

Some patients had more than one side effect due to treatment.

###### 

Disease status at the time of initiation and completion of 12-month therapy with IFN-α + GM-CSF.

  **Status**   **Prior**                                         **At completion**
  ------------ ------------------------------------------------- -------------------
  PR           9[\*](#tfn12-cmo-2010-117){ref-type="table-fn"}   3
  CR           5                                                 8
  VGPR         12                                                9
  Relapse      N/A                                               6

**Note:**

Results reflect number of patients in each response category.

###### 

Effect of IFN-α/GM-CSF maintenance in high risk myeloma patients, as defined by the presence of β2M \> 4 mg/L and/or del 13/13q and/or complex chromosomal abnormalities at diagnosis.

  **Subject**   **β2M; Repeat**   **Disease stage**   **PFS (mo)**   **OS (mo)**   **Cytogenetic/FISH**           **Status**
  ------------- ----------------- ------------------- -------------- ------------- ------------------------------ ------------
  1             9.2; 9.8          IIIB                12             32            Normal                         Dead
  2             4.3; 2.9          IIIA                9              12            Normal                         Dead
  3             7.7; 6.4          IIIB                40             58            Normal                         Alive
  4             5.8; 2.7          IIIB                11             25            Complex (49, −X and 13q del)   Dead
  5             8.8; 2.5          IIA                 58             58            Normal                         Alive
  6             9.6; 4.6          IIB                 39             39            Normal                         Alive
  7             2.2; 2.4          IIA                 14             20            13 del/Complex                 Dead
  8             2.0; 2.6          IA                  12             28            13q del                        Alive

**Abbreviations:** del, deletion; complex, multiple chromosomal abnormalities (\>3).
